Inherent Anticipation

Inherent anticipation is a doctrine under 35 U.S.C. § 102 that invalidates a patent claim when a prior art reference, while not explicitly disclosing a claimed feature, necessarily results in or produces that feature. Under normal anticipation, a prior art reference must explicitly disclose every element of the claimed invention. Under inherent anticipation, a prior art reference can anticipate a claim even if it does not explicitly mention a claimed feature — as long as that feature is necessarily present when the prior art's described method is practiced or product is made. The standard: the claimed feature must be NECESSARILY PRESENT — it is not enough that the feature MIGHT be present or is occasionally present in the prior art; it must be inherent in what the prior art describes.

The 'necessarily present' test requires showing that when the prior art's described process, product, or method is practiced exactly as described, the claimed feature will ALWAYS result — not just sometimes, not on average, but inevitably and necessarily. The test is demanding: (1) ALWAYS, NOT SOMETIMES — if the claimed feature is only sometimes produced by the prior art process, it is not inherently anticipated (Hansgirg v. Kemmer, C.C.P.A. 1939: a result that 'naturally and necessarily flows from the prior art' vs. a result that only sometimes occurs); (2) NECESSARY RESULT, NOT OBVIOUS RESULT — the fact that a skilled artisan could predict or expect the result does not make it inherent; it must be the INEVITABLE result; (3) RECOGNITION NOT REQUIRED — one key aspect of inherency: the persons practicing the prior art process did NOT need to recognize or appreciate that the inherent feature was present. If the feature necessarily results, it does not matter that no one knew it at the time. Recognition (or lack of it) goes to anticipation of method claims requiring a 'knowing' element, not to pure product or property claims.

SCHERING CORP. v. GENEVA PHARMACEUTICALS (Fed. Cir. 2003): Schering held patents on descarboethoxyloratadine (DCL), an active metabolite of loratadine (the antihistamine in Claritin). Schering argued the prior art did not specifically disclose DCL. The Federal Circuit held that when patients took loratadine as described in the prior art, their bodies metabolized it into DCL — this was an inherent result of the prior art's disclosed use. The patients' bodies produced DCL whether they knew it or not. DCL was inherently anticipated. TITANIUM METALS CORP. v. BANNER (Fed. Cir. 1985): A Soviet scientific paper described a titanium alloy composition. The alloy's corrosion resistance was not mentioned in the paper. Titanium Metals sought a patent claiming the same alloy composition because of its corrosion resistance. The Federal Circuit held: the alloy composition was anticipated by the Soviet paper — the corrosion resistance was an inherent property of the alloy; the Soviet paper did not need to describe the property; the composition necessarily had that property. ABBOTT LABORATORIES v. BAXTER PHARMACEUTICAL PRODUCTS (Fed. Cir. 2005): prior art mixing processes necessarily produced a product with certain claimed properties — inherent anticipation applied even though the prior art makers did not measure or appreciate the properties.

No — recognition is not required for inherent anticipation of product or composition claims. As established in Schering and Titanium Metals: a prior art product inherently possesses a property whether or not anyone recognized the property at the time. If the Soviet paper described the titanium alloy and that alloy inherently has corrosion resistance, the corrosion resistance is anticipated regardless of whether the Soviet scientists knew about it. EXCEPTION FOR METHOD CLAIMS: for method claims that include a mental step or a step requiring knowledge (e.g., 'a method comprising identifying a compound having property X'), the analysis is different — a prior art method that produced the compound without identifying property X may not anticipate a claim requiring the knowing identification. COMPARISON TO OBVIOUSNESS: Schering noted that even if the inherent feature was unknown and unrecognized in the prior art, this does not make the patent eligible by transforming it from anticipated to novel — if the feature is inherent, it is anticipated (§ 102), and novelty requires every element to be new, not just recognized.

INHERENT ANTICIPATION (§ 102): a single prior art reference necessarily produces or includes the claimed element — even without explicit disclosure; does not require combining references; the claimed element MUST always result from the prior art. OBVIOUSNESS (§ 103): multiple prior art references, or a single reference combined with common knowledge, render the claimed invention obvious to a person of ordinary skill; does not require that the result be certain — only that a skilled artisan would have been motivated to combine and had a reasonable expectation of success. KEY DISTINCTION: inherent anticipation requires inevitability; obviousness allows for reasoning, motivation, and expectation. A property that only sometimes results from a prior art process is NOT inherently anticipated (fails inevitability) but might still be rendered obvious if a skilled artisan would have predictably expected it. Practical use: when arguing prior art against a patent, consider both inherent anticipation (if the feature always results from the prior art as described) AND obviousness (if the feature is not inevitable but predictable).